Cargando…

Allogeneic natural killer cell therapy

Interest in adoptive cell therapy for treating cancer is exploding owing to early clinical successes of autologous chimeric antigen receptor (CAR) T lymphocyte therapy. However, limitations using T cells and autologous cell products are apparent as they (1) take weeks to generate, (2) utilize a 1:1...

Descripción completa

Detalles Bibliográficos
Autores principales:	Berrien-Elliott, Melissa M., Jacobs, Miriam T., Fehniger, Todd A.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	The American Society of Hematology 2023
Materias:	Banked Allogeneic Immune Effector Cells
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10023727/ https://www.ncbi.nlm.nih.gov/pubmed/36416736 http://dx.doi.org/10.1182/blood.2022016200

Ejemplares similares

Genome-edited allogeneic donor “universal” chimeric antigen receptor T cells
por: Qasim, Waseem
Publicado: (2023)

Banking on virus-specific T cells to fulfill the need for off-the-shelf cell therapies
por: Quach, David H., et al.
Publicado: (2023)

Engineered and banked iPSCs for advanced NK- and T-cell immunotherapies
por: Cichocki, Frank, et al.
Publicado: (2023)

Peptide: MHC-based DNA vaccination strategy to activate natural killer cells by targeting killer cell immunoglobulin-like receptors
por: Rettman, Pauline, et al.
Publicado: (2021)

Chemical priming of natural killer cells with branched polyethylenimine for cancer immunotherapy
por: Choi, Seung Hee, et al.
Publicado: (2022)

Identification of Respiratory Viral Infection in Hematopoietic Stem Cell Transplant Recipients - Impact on Non Relapse Mortality
por: Imlay-Gillespie, Louise, et al.
Publicado: (2015)

Individual dynamics of uterine natural killer cells in natural and stimulated cycles monitored using a new endometrial dating method
por: Alfer, Joachim, et al.
Publicado: (2022)

'Off-the-shelf’ allogeneic antigen-specific adoptive T-cell therapy for the treatment of multiple EBV-associated malignancies
por: Sinha, Debottam, et al.
Publicado: (2021)

Targeting human leukocyte antigen G with chimeric antigen receptors of natural killer cells convert immunosuppression to ablate solid tumors
por: Jan, Chia-Ing, et al.
Publicado: (2021)

Bispecific antibody-mediated redirection of NKG2D-CAR natural killer cells facilitates dual targeting and enhances antitumor activity
por: Zhang, Congcong, et al.
Publicado: (2021)

Intrinsic suppression of type I interferon production underlies the therapeutic efficacy of IL-15-producing natural killer cells in B-cell acute lymphoblastic leukemia
por: Kumar, Anil, et al.
Publicado: (2023)

Use of cytokine-induced killer cell therapy in patients with colorectal cancer: a systematic review and meta-analysis
por: Li, Celine Man Ying, et al.
Publicado: (2023)

Metastasis-associated macrophages constrain antitumor capability of natural killer cells in the metastatic site at least partially by membrane bound transforming growth factor β
por: Brownlie, Demi, et al.
Publicado: (2021)

S129: ADOPTIVELY INFUSED MEMORY-LIKE (ML) NATURAL KILLER (NK) CELLS ELICIT ADAPTIVE IMMUNE RESPONSES IN PATIENTS WITH ACUTE MYELOID LEUKEMIA (AML)
por: Rutella, Sergio, et al.
Publicado: (2023)

Targeting T-cell malignancies using allogeneic double-negative CD4-CAR-T cells
por: Fang, Karen Kai-Lin, et al.
Publicado: (2023)

Acute macular outer retinopathy as a presumed manifestation of COVID-19
por: El Matri, K., et al.
Publicado: (2021)

Impact of COVID-19 pandemic on an iris metastasis
por: Lemaître, S., et al.
Publicado: (2021)

Antibody Response to Sars-Cov-2 Vaccination in Patients Following Allogeneic Hematopoietic Cell Transplantation
por: Cicin-Sain, Caroline, et al.
Publicado: (2021)

Eye banking: an introduction
por: Rao, Gullapalli N, et al.
Publicado: (2009)

Optic neuropathy in a COVID-19 patient
por: Borrego-Sanz, L., et al.
Publicado: (2021)

High-affinity CD16 integration into a CRISPR/Cas9-edited CD38 locus augments CD38-directed antitumor activity of primary human natural killer cells
por: Clara, Joseph Andrew, et al.
Publicado: (2022)

Presence of Natural Killer B Cells in Simian Immunodeficiency Virus-Infected Colon That Have Properties and Functions Similar to Those of Natural Killer Cells and B Cells but Are a Distinct Cell Population
por: Cogswell, Andrew, et al.
Publicado: (2022)

Combinatorial immunotherapy of N-803 (IL-15 superagonist) and dinutuximab with ex vivo expanded natural killer cells significantly enhances in vitro cytotoxicity against GD2(+) pediatric solid tumors and in vivo survival of xenografted immunodeficient NSG mice
por: Chu, Yaya, et al.
Publicado: (2021)

Antibody Response to 2-Dose Sars-Cov-2 mRNA Vaccine in Allogeneic Hematopoietic Cell Transplant Recipients
por: Maillard, Alexis, et al.
Publicado: (2021)

Response to BNT162b2 Sars-Cov-2 Vaccine in Recipients of Allogeneic Hematopoietic Stem Cell Transplant
por: Saraceni, Francesco, et al.
Publicado: (2021)

Incidence and Predictors of Sars-Cov-2 Antibody Responses Following COVID-19 Vaccination in Allogeneic Stem Cell Transplant Recipients
por: Minehart, Janna C., et al.
Publicado: (2021)

CD56 regulates human NK cell cytotoxicity through Pyk2
por: Gunesch, Justin T, et al.
Publicado: (2020)

Sars-Cov-2 T-Cell Response in Allogeneic Hematopoietic Stem Cell Recipients Following Two Doses of BNT162b2 Vaccine
por: Clemenceau, Beatrice, et al.
Publicado: (2021)

COVID-19 Vaccination after Allogeneic Stem Cell Transplantation: Real Word Data on Safety and Efficacy. a Single Center Experience.
por: Neagoie, Adela, et al.
Publicado: (2021)

Erbu Zhuyu decoction improves endometrial angiogenesis via uterine natural killer cells and the PI3K/Akt/eNOS pathway a mouse model of embryo implantation dysfunction
por: Shen, Mengmeng, et al.
Publicado: (2022)

Low Frequency of T Cell and Antibody Responses to Vaccination Against Sars-Cov-2 in Patients Post Allogeneic Stem Cell Transplantation in Comparison with Chronic Myeloid Malignancy Patients
por: Harrington, Patrick, et al.
Publicado: (2021)

Natural killer cell‐mediated ADCC in SARS‐CoV‐2‐infected individuals and vaccine recipients
por: Hagemann, Kerri, et al.
Publicado: (2022)

Limited efficacy of APRIL CAR in patients with multiple myeloma indicate challenges in the use of natural ligands for CAR T-cell therapy
por: Lee, Lydia, et al.
Publicado: (2023)

Interest of a Third Dose of BNT162b2 Anti- Sars-Cov-2 mRNA Vaccine in Allogeneic Hematopoietic Stem-Cells Recipients
por: Le Bourgeois, Amandine, et al.
Publicado: (2021)

Peptidylprolyl isomerase C (Ppic) regulates invariant Natural Killer T cell (iNKT) differentiation in mice
por: Paiva, Ricardo S., et al.
Publicado: (2021)

Killing of Kaposi's sarcoma-associated herpesvirus-infected fibroblasts during latent infection by activated natural killer cells
por: Matthews, Nick C, et al.
Publicado: (2011)

Profound B-Cell Lymphopenia Is a Major Factor Predicting Poor Humoral Response after BNT162b2 mRNA Sars-Cov-2 Vaccines in Recipients of Allogeneic Hematopoietic Stem Cell Transplantation
por: Jullien, Maxime, et al.
Publicado: (2021)

MicroRNA regulation of natural killer cells
por: Sullivan, Ryan P., et al.
Publicado: (2013)

The effect of the sympathetic nervous system on splenic natural killer cell activity in mice administered the Lactobacillus pentosus strain S-PT84
por: Izumo, Takayuki, et al.
Publicado: (2013)

Flow cytometry-based ex vivo murine NK cell cytotoxicity assay
por: Wong, Pamela, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_a2n9ujk545jks7oslp4du0pt9k